| Transaction Date | Recipient | Shares | Type | Price | Value |
|---|---|---|---|---|---|
| 10th September 2020 | Mark A Goldsmith | 2,544 | Open or private sale | $29.07 | $73,947.72 |
| 10th September 2020 | Mark A Goldsmith | 4,399 | Open or private sale | $29.00 | $127,571.00 |
| 10th September 2020 | Mark A Goldsmith | 2,544 | Exercise of derivative | $1.12 | $2,849.28 |
| 9th September 2020 | Mark A Goldsmith | 100 | Open or private sale | $29.00 | $2,900.00 |
| 8th September 2020 | Mark A Goldsmith | 900 | Exercise of derivative | $1.12 | $1,008.00 |
| 8th September 2020 | Mark A Goldsmith | 900 | Open or private sale | $29.05 | $26,140.86 |
| 8th September 2020 | Mark A Goldsmith | 900 | Open or private sale | $29.05 | $26,145.00 |
| 3rd September 2020 | Mark A Goldsmith | 700 | Open or private sale | $29.07 | $20,352.01 |
| 3rd September 2020 | Mark A Goldsmith | 500 | Open or private sale | $29.07 | $14,533.00 |
| 3rd September 2020 | Mark A Goldsmith | 500 | Exercise of derivative | $1.12 | $560.00 |
Constellation Pharmaceuticals
Constellation Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It engages in the development of novel therapeutics in the field of epigenetics. Its product candidates include CPI-0610, CPI-1205, and CPI-0209.
Ticker: CNST
Sector: Health Technology
Industry: Pharmaceuticals: Major
SEC Central Index Key (CIK): 1434418
Employees: 106
Exchange: NASDAQ
Auditor Opinion:
You must Login to see Language Changes
Disclosure Language changes
You must Login to see analysis
Red Flags
There were no Red Flags found
Fundamentals
Cash at Carrying Value: $179 M (0%)
Marketable Securities, Current: $341 M (588%)
Assets, Current: $523 M (35%)
Property, Plant and Equipment, Net: $1 M (48%)
Assets: $535 M (33%)
Long-term Debt, Current Maturities: $2 M (0%)
Accounts Payable, Current: $6 M (-22%)
Liabilities, Current: $27 M (19%)
Long-term Debt, Excluding Current Maturities: $28 M (0%)
Other Liabilities, Noncurrent: $716 Th (83%)
Liabilities: $63 M (2%)
Common Stock, Value, Issued: $5 Th (25%)
Common Stock, Shares, Issued: $48 M (13%)
Additional Paid in Capital, Common Stock: $846 M (28%)
Retained Earnings (Accumulated Deficit): $375 M (0%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $255 Th (4150%)
Stockholders' Equity (Parent): $472 M (0%)
Liabilities and Equity: $535 M (33%)
Research and Development: $23 M (-47%)
General and Administrative Expenses: $7 M (-45%)
Operating Income/Loss: $30 M (-46%)
Other Income, net: $142 Th (-65%)
Provision for income taxes: $24 Th (-38%)
